Sagimet Biosciences (SGMT)

• Market cap: $111M
• 1 day: 0.88%
• 5 days: 23.21%
• 1 month: 5.83%
• 3 months: -15.02%
• 6 months: -35.39%
• Year to date: -23.16%
• 1 year: -11.54%
• 5 years: -78.37%
• 10 years: -78.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

45% more capital invested

Capital invested by funds: $54.4M [Q3] → $78.8M (+$24.3M) [Q4]

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

5% more funds holding

Funds holding: 63 [Q3] → 66 (+3) [Q4]

7.03% less ownership

Funds ownership: 64.07% [Q3] → 57.04% (-7.03%) [Q4]

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

78% less call options, than puts

Call options by funds: $281K | Put options by funds: $1.26M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $32 828% upside
• Avg. target: $32 828% upside
• High target: $32 828% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 40% 1-year accuracy 61 / 151 met price target

828% upside $32

Buy Reiterated

13 Mar 2025